Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer

BMC Cancer

Table 2 Exposures to ≥ 90 days of COX-2 inhibitors, ns-NSAIDs, aspirin and acetaminophen in the year prior to the index date: Crude and adjusted odds ratios.

Exposure to ≥ 90 days	Cases N of patients (%)	Controls N of patients (%)	Crude odds ratios	Adjusted odds ratios*
Ns-NSAID/COX-2 inhibitors	186 (17.1)	8,681 (19.3)	0.70 (0.59, 0.84)	0.75 (0.64, 0.89)
COX-2 inhibitors	166 (15.2)	7,412 (16.5)	0.73 (0.61, 0.88)	0.81 (0.68, 0.97)
Rofecoxib	76 (7.0)	3,597 (8.0)	0.69 (0.54, 0.89)	0.80 (0.63, 1.02)
Celecoxib	93 (8.5)	3,792 (8.4)	0.80 (0.64, 1.00)	0.88 (0.70, 1.10)
Ns-NSAIDs	24 (2.2)	1,278 (2.8)	0.61 (0.40, 0.93)	0.65 (0.43, 0.99)
Aspirin
average daily dose ≤ 100 mg/day	78 (7.2)	2,894 (6.4)	0.88 (0.69, 1.13)	0.91 (0.71, 1.16)
average daily dose >100 mg/day^#	211 (19.4)	8,419 (18.7)	0.82 (0.69, 0.97)	0.75 (0.64, 0.89)
Acetaminophen	74 (6.8)	2,534 (5.6)	0.95 (0.74, 1.23)	0.91 (0.71, 1.16)
Not exposed ^§	375 (34.4)	12,260 (27.3)	1 (Reference)	1(Reference)

* Adjusted for age, mammography in years 2 or 3 prior to index date, breast procedure in the prior 3 years, benign neoplasm of the breast in the prior 3 years, other breast disease in the prior 3 years, estrogen replacement therapy in the prior year, and visit to a gynecologist in the prior year- these variables were risk factors for breast cancer but their inclusion in the model did not alter substantially the effect of exposure to the drugs of interest.
^#90% of all aspirin prescriptions were for ≤ 325 mg/day
^§Not exposed refers to the group of patients who were not exposed to ns-NSAIDs, aspirin, COX-2 inhibitors or acetaminophen during the year prior to the index date

ISSN: 1471-2407